New asthma drug IBI3002 tested in first human trial
NCT ID NCT06213844
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested a single dose of the experimental drug IBI3002 in 52 healthy volunteers and people with mild to moderate asthma. The main goal was to check safety and how the body processes the drug. Researchers monitored side effects and drug levels in the blood over five weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3002
- What this could lead to
- If successful, this could point toward a new treatment option for asthma that helps control symptoms.
- What could go wrong
- This is a very early Phase 1 trial with only 52 participants, focused on safety, not effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can tracking severe asthma over time unlock better treatments?
- Can a new injection help tackle obesity? a safety trial begins
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Will a new pill formula absorb the same? a trial puts it to the test